MRTX-1719
- Generic Name
- MRTX-1719
- Drug Type
- Small Molecule
- Chemical Formula
- C23H18ClFN6O2
- CAS Number
- 2630904-44-6
- Unique Ingredient Identifier
- AY4A8WD6JS
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
- Conditions
- MesotheliomaNon Small Cell Lung CancerMalignant Peripheral Nerve Sheath TumorsSolid TumorPancreatic AdenocarcinomaAdvanced Solid Tumor
- Interventions
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 320
- Registration Number
- NCT06937970
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Rocky Mountain Cancer Centers, LLP - Oncology, Lone Tree, Colorado, United States
🇺🇸Sarah Cannon Research Institute (SCRI) - HealthONE Location, Denver, Colorado, United States
Clinical Trial of BMS-986504 in Recurrent GBM Patients
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Nader Sanai
- Target Recruit Count
- 9
- Registration Number
- NCT06883747
- Locations
- 🇺🇸
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion
- First Posted Date
- 2025-03-04
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 130
- Registration Number
- NCT06855771
- Locations
- 🇺🇸
Local Institution - 0088, Anchorage, Alaska, United States
🇺🇸Local Institution - 0099, Boise, Idaho, United States
🇺🇸Local Institution - 0090, Boston, Massachusetts, United States
A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion
- Conditions
- Advanced Solid Tumors With Homozygous MTAP Deletion
- Interventions
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 8
- Registration Number
- NCT06672523
- Locations
- ðŸ‡ðŸ‡º
ICON / PRA Magyarország Kft. Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Budapest, Hungary
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
- Conditions
- Pancreatic AdenocarcinomaNon Small Cell Lung CancerAdvanced Solid TumorMalignant Peripheral Nerve Sheath TumorsMesotheliomaSolid Tumor
- Interventions
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 320
- Registration Number
- NCT05245500
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers, LLP - Oncology, Lone Tree, Colorado, United States
🇺🇸Cancer and Hematology Centers of Western Michigan, Norton Shores, Michigan, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.